Reticulocyte Hemoglobin Content Helps Avoid Iron Overload in Hemodialysis Patients: A Retrospective Observational Study [PDF]
, 2017 Anemia in patients suffering from end-stage renal failure is currently treated with Erythropoiesis-Stimulating Agents (ESA). This treatment needs sufficient iron supplementation to avoid an inadequate dosage of ESA. Nowadays modern analytical instruments
Barretta, Luca +9 more
core
A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. [PDF]
J Am Soc Nephrol, 2021 Toto R +6 more
europepmc +1 more source
Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD. [PDF]
J Am Soc Nephrol, 2021 Nangaku M +7 more
europepmc +1 more source
Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients. [PDF]
Ther Apher Dial, 2021 Akizawa T +3 more
europepmc +1 more source
Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. [PDF]
Nephrol Dial Transplant, 2021 Nangaku M +7 more
europepmc +1 more source
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia [PDF]
, 2011 Chris L. Pashos +5 more
core +1 more source
Regulação da produção da eritropoietina e perspectivas terapêuticas na anemia [PDF]
, 2015 About 30 years ago, the treatment of chronic renal disease anaemia was revolutionized by the introduction of recombinant human erythropoietin, which reduced the need for blood transfusions.
Almeida, F., Beirão, I., Santos, S.
core
Nursing: Research and Reviews, 2013 Loraine Derbyshire, Colin W Thain School of Health, University of Central Lancashire, Preston, United Kingdom Abstract: Chemotherapy induced anemia (CIA) is a frequent complication of anticancer treatment, but often remains untreated. The main presenting
Derbyshire L, Thain CW
doaj
Innovation and market dynamics in the EPO market [PDF]
, 2006 We have estimated the demand of erythropoietin (EPO) on market data from the Nordic countries. Assuming that prices are set in a Nash-Bertrand game we determine the degree of competition in this Nordic market.
Sorisio, Enrico, Strøm, Steinar
core